Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.52 |
| ▸ | FABP7 | O15540 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358709 | 0.85 | FABP5 (0.54) | FABP5FABP7KMT2AALDH1A1KDM4E | |
| SCHEMBL31398326 | 0.82 | KDM4E (0.46) | FABP5FABP7KMT2AALDH1A1KDM4E | |
| SCHEMBL31505489 | 0.82 | KDM4E (0.46) | FABP5FABP7KMT2AALDH1A1KDM4E | |
| SCHEMBL119822 | 0.82 | KDM4E (0.46) | FABP5FABP7KMT2AALDH1A1KDM4E | |
| SCHEMBL30481198 | 0.82 | KDM4E (0.46) | FABP5FABP7KMT2AALDH1A1KDM4E | |
| SCHEMBL31652744 | 0.82 | KMT2A (0.50) | FABP5FABP7KMT2AOPRD1SMN1; SMN2 | |
| SCHEMBL1763711 | 0.82 | KMT2A (0.50) | FABP5FABP7KMT2AOPRD1SMN1; SMN2 | |
| SCHEMBL30928197 | 0.81 | FABP5 (0.58) | FABP5FABP7KMT2AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL31688509 | 0.81 | KMT2A (0.49) | FABP5FABP7KMT2AOPRD1SMN1; SMN2 | |
| Water SCHEMBL4955373 | 0.81 | KDM4E (0.45) | FABP5FABP7KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | FABP5 2355/4885FABP7 2926/4885KMT2A 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.